LMTX (also known as TRX0237) is a tau aggregation inhibitor developed by TauRx Pharmaceuticals, a company spun out from the University of Aberdeen. Originally branded as LMTX, the compound has been repositioned and is now being developed under the name HMTM (Hydromethylthioninium). This represents one of the longest-running tau-targeted drug development programs in history.
The methylthioninium core was discovered in 1996 by Professor Claude Wischik and colleagues at the University of Aberdeen. The original compound was identified for its ability to dissolve tau filaments and neurofibrillary tangles in vitro.
LMTX/HMTM is a tau aggregation inhibitor with multiple proposed mechanisms:
TauRx conducted the first Phase II trial from 2001-2008, establishing initial safety and efficacy signals in Alzheimer's disease patients.
Two Phase III trials were conducted in 2012-2016:
Results announced in 2017 showed "pharmacological activity on clinical decline and brain atrophy," though the effects were modest.
Starting in 2020, TauRx initiated the LUCIDITY Phase III program in North America and Europe:
In 2022, TauRx announced top-line results from LUCIDITY. The results were submitted to the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for approval as a tablet formulation for MCI and mild-to-moderate Alzheimer's disease.
The LMTX program has been subject to significant scientific scrutiny:
Despite criticism, TauRx has continued development based on the totality of evidence from multiple trials.
The tau aggregation inhibitor approach targets the fundamental pathological process in tauopathies:
| Approach | Mechanism | Advantages | Limitations |
|---|---|---|---|
| LMTX/HMTM | Aggregation inhibitor | Oral, targets assembled tau | Modest efficacy, controversy |
| Anti-tau antibodies | Immunotherapy | IV delivery, established | N-terminal antibodies failed |
| ASOs (BIIB080) | Gene silencing | 50-60% tau reduction | Intrathecal delivery |
| OGA inhibitors | O-GlcNAcylation | Oral, upstream target | Clinical proof pending |
As of 2024, HMTM has been submitted for regulatory approval in the UK. The MHRA decision is pending. If approved, HMTM could become the first disease-modifying treatment for Alzheimer's disease targeting tau pathology.
The methylthioninium core (MT) was originally discovered for its ability to directly bind to paired helical filament (PHF) tau and promote disassembly[1]. The compound exhibits high affinity for tau aggregates:
Beyond targeting assembled filaments, LMTX/HMTM also addresses soluble toxic oligomers[2]:
The compound may provide neuroprotective effects through antioxidant mechanisms[3]:
The tau aggregation inhibitor approach differs fundamentally from other small molecule strategies[4]:
| Target | Example Drugs | Mechanism | Stage |
|---|---|---|---|
| Aggregation inhibitors | LMTX/HMTM, Methylene blue | Dissolve PHF/SF | Phase III |
| Kinase inhibitors | Tideglusib, Lithium | Reduce phosphorylation | Phase II |
| O-GlcNAcylation | LY3372689, ASN90 | Increase O-GlcNAc | Phase II |
| Microtubule stabilators | Davunetide | Enhance microtubule function | Discontinued |
The Phase II trials (2001-2008) provided initial evidence of pharmacological activity[5]:
Study Design:
Results:
Publication: Results published in JAMA Psychiatry 2018[5:1].
Two Phase III trials were conducted in mild-to-moderate AD and FTD[5:2]:
Key Findings:
Interpretation Issues:
The LUCIDITY program represents the most comprehensive evaluation of HMTM[6]:
Study Design:
Results Summary:
| Trial | Phase | Status | NCT Number |
|---|---|---|---|
| Study 1 | II | Completed | NCT01689246 |
| Study 2 | II | Completed | NCT01689246 |
| LUCIDITY | III | Completed | NCT03098784 |
| OLE | III | Completed | NCT03458429 |
TauRx Pharmaceuticals represents a unique case in CNS drug development:
Company Origins:
Development Philosophy:
Financial Model:
Pipeline Beyond HMTM:
The LMTX/HMTM program has faced significant scientific scrutiny[5:3]:
1. Modest Effect Sizes:
2. Post-hoc Analysis Concerns:
3. Concomitant Medication Confound:
4. Independent Replication:
TauRx has defended the program based on[1:1]:
United Kingdom:
European Union:
United States:
Understanding where HMTM fits in the broader tau therapeutic landscape:
| Drug/Approach | Company | Mechanism | Phase | Status |
|---|---|---|---|---|
| LMTX/HMTM | TauRx | Aggregation inhibitor | III | Submitted UK |
| Semorinemab | Roche | N-terminal antibody | II | Failed |
| Gosuranemab | Biogen | N-terminal antibody | II | Discontinued |
| E2814 | Eisai | MTBR antibody | III | Ongoing |
| BIIB080 | Biogen | ASO | II | Ongoing |
| LY3372689 | Lilly | OGA inhibitor | II | Ongoing |
Key Insight: If approved, HMTM would be the first oral tau-targeting drug, representing a fundamentally different mechanism than antibody-based approaches.
Wischik CM, et al. Tau aggregation inhibitors as disease-modifying therapy for Alzheimer's disease. Biochemical Society Transactions. 2021. ↩︎ ↩︎
Hurley MJ, et al. Tau aggregation inhibitors: a new therapeutic approach for Alzheimer's disease and tauopathies. Neuropharmacology. 2020. ↩︎
Atzori M, et al. Redox dysregulation in Alzheimer's disease: therapeutic implications of antioxidants. Free Radical Biology and Medicine. 2020. ↩︎
Soeda Y, et al. Small molecule inhibitors of tau aggregation: current status and future directions. Alzheimer's Research & Therapy. 2022. ↩︎
Gauthier S, et al. Effect of LMTX in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, parallel-group, monotherapy study. JAMA Psychiatry. 2018. ↩︎ ↩︎ ↩︎ ↩︎
Baddeley TC, et al. LUCIDITY: Results from a 12-month open-label extension study. Alzheimer's & Dementia. 2022. ↩︎